Selami Bayram

Dr. Selami Bayram

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2019 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
DSDerya Kivrak Salim
Derya Kivrak Salim
SBSelami Bayram
Selami Bayram
IGİsMail Gömceli
İsMail Gömceli
AÇAyhan Hilmi Çekin
Ayhan Hilmi Çekin
MKMustafa Karaca
Mustafa Karaca
MYMustafa Yıldız
Mustafa Yıldız
Background/Aims: Gastroenteropancreatic neuroendocrine tumors are rarely seen and have heterogeneous clinical outcomes. Mostly half of the patients had metastatic disease at presentation. Palliative resection of primary site in metastatic disease is still controversial. The aim of this study was to find out the influence of resection of primary tumor site on progression-free survival and overall survival in metastatic non-functioning gastroenteropancreatic neuroendocrine tumors. The secondary end point is to determine the prognostic factors influencing the survivals. Materials and Methods: This study was conducted at a single medical oncology center, Antalya Education and Research Hospital. Patients who had non-functioning metastatic gastroenteropancreatic neuroendocrine tumors with primary site resected or unresected were compared retrospectively. Resection of metastases was excluded. Results: Fifty-three patients were included in the study and 29 patients had primary tumor resection. The primary site resected group had favorable outcomes with the overall survival (median unreached) compared to the median overall survival of 30 months in the unresected group (p=0.001). Median progression-free survival was also better in the primary site resected group than the unresected group (60 months vs. 14 months, respectively) (p=0.013). In multivariate analysis, unresected primary site and high-grade tumors were found to be independent prognostic factors on low survivals (Hazard ratio (HR): 4.6; 95% CI: 1.21-17.47 and HR: 10.1; 95% CI: 1.15-88.84, respectively). Age (p=0.131), gender (p=0.051), chromogranin A level (p=0.104), Ki-67 index (p=0.550), tumor size (p=0.623), and primary tumor area (p=0.154) did not influence the overall survival. Conclusion: Gastroenteropancreatic neuroendocrine tumors with primary site resected had improved survivals when compared to the unresected group.

15 February 2026 in Medicina
Verified
Journal Article
Open access
PDF file
SBSelami Bayram
Selami Bayram
MAMustafa Serkan Serkan Alemdar
Mustafa Serkan Serkan Alemdar
ATAli Murat Tatli
Ali Murat Tatli
DSDerya Kivrak Salim
Derya Kivrak Salim
BOBanu Ozturk
Banu Ozturk
MOMustafa Ozdogan
Mustafa Ozdogan
Background and Objectives: Glioblastoma (GBM), defined as IDH-wildtype CNS WHO grade 4, remains the most common and aggressive primary malignant brain tumor in adults. Although the extent of resection (EOR), particularly gross total resection (GTR), is considered a potentially modifiable factor, survival comparisons across surgical groups are vulnerable to selection bias and unmeasured biological confounding. We evaluated the association between GTR and survival outcomes in patients with newly diagnosed IDH-wildtype GBM in a dual-center, real-world cohort. Materials and Methods: We conducted a retrospective, dual-center cohort study of 100 adult patients with histopathologically confirmed GBM who underwent primary surgical resection between 2015 and 2021. GTR was defined as no measurable residual contrast-enhancing tumor on early postoperative MRI (≤72 h). All patients received adjuvant chemoradiotherapy according to the Stupp protocol. Survival was analyzed using Kaplan–Meier methods with log-rank tests and explored using univariable Cox regression analysis. Given the missing key prognostic covariates (notably MGMT promoter methylation) and the retrospective design, the analyses were reported as unadjusted and descriptive. Results: Of the 100 patients, 63 (63%) underwent GTR and 37 (37%) non-GTR. The GTR group had a significantly higher rate of radiologic complete response (42.9% vs. 10.8%, p = 0.001). However, no significant differences were observed in overall survival (OS; median 13 vs. 12 months, p = 0.847) or progression-free survival (PFS; 8 vs. 8 months, p = 0.963) between the groups in unadjusted analyses. Long-term Kaplan–Meier estimates (e.g., 5-year OS) should be interpreted cautiously due to the small number of patients at risk and potential selection and biological confounding. Conclusions: In this dual-center cohort, GTR was associated with improved radiologic response but not with longer OS or PFS in unadjusted analyses. These results should be considered hypothesis-generating and not interpreted as evidence against maximal safe resection. The absence of MGMT promoter methylation status, lack of volumetric EOR quantification (including non-contrast-enhancing/FLAIR disease), and lack of standardized functional outcome data substantially limited causal inference. Prospective studies integrating molecular stratification, volumetric resection metrics, and functional outcome assessments are warranted.

24 December 2022 in Cumhuriyet Medical Journal
Verified
Journal Article
Open access
PDF file
AÖArif Hakan Hakan Önder
Arif Hakan Hakan Önder
DSDerya Kivrak Salim
Derya Kivrak Salim
MKMustafa Karaca
Mustafa Karaca
SBSelami Bayram
Selami Bayram
Asim Armagan AydinAsim Armagan Aydin
Asim Armagan Aydin
BOBanu Ozturk
Banu Ozturk
Introduction and Aim: Cancer affects people psychologically and organically. The emotional state of cancer patients is fragile and can be affected by many factors. We aimed to evaluate the effect of the COVID-19 pandemic on the mood and behavioral changes of cancer patients with solid cancer who are in follow-up and treatment. Material and Method: A face-to-face questionnaire was filled in solid cancer patients without known psychological disorders who applied to the Medical Oncology outpatient clinic between 1-30 September 2021. The Hospital Anxiety and Depression Scale (HADS) and the scale examining the perspectives on COVID-19 were applied to the patients whose consent was obtained. Results: A total of 235 people, participated in the survey. In the review of 202 completed surveys, 139 women and 63 men and the median age was 55 (23-83 years). In the study in which seventeen different solid cancer patients were evaluated, breast (52.5%), colon (19.3%) and lung (10.8%) cancers were most common. Most of the people who were more afraid of COVID-19 compared to cancer were patients who were on active cancer treatment. In the multivariate regression analysis, being on active treatment was found to be the only risk factor for 'being more afraid of COVID-19' compared to cancer. During COVID-19 pandemic, it was observed that 18 (8.9%) patients delayed their treatment/follow-up due to fear of COVID-19 infection. A high HADS anxiety score was observed in 58 (28.7%) patients, and a high HADS depression score was observed in 39 patients (19.3%). Conclusion: Cancer patients are seriously worried about the progression of their cancer due to changes in follow-up or treatment due to COVID-19 pandemic. However, despite the associated risks, they were found to want to continue their treatment as planned.

1 December 2025 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
SBSelami Bayram
Selami Bayram
MAMustafa Serkan Alemdar
Mustafa Serkan Alemdar
ATAli Murat Tatli
Ali Murat Tatli
MOMustafa Ozdogan
Mustafa Ozdogan
Pathological complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC) is associated with favorable outco

28 October 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
SBSelami Bayram
Selami Bayram
ATAli Murat Tatli
Ali Murat Tatli
MCMuharrem Okan Cakir
Muharrem Okan Cakir
MOMustafa Ozdogan
Mustafa Ozdogan
Background: Pathologic complete response (pCR) after neoadjuvant systemic therapy (NAST) is a key prognostic marker in early breast cancer (EBC), particularly in triple-negative (TNBC) and HER2-positive subtypes. However, real-world data on predictors of pCR and their impact on survival remain limited. Methods: We retrospectively analyzed 200 patients with stage II–III EBC treated with NAST at a single institution (2015–2023). Clinicopathologic variables and treatment characteristics were evaluated for association with pCR (ypT0/is ypN0), and histological regression was additionally assessed using the Miller–Payne scoring system. Multivariable logistic regression identified independent predictors. Disease-free survival (DFS) and overall survival (OS) were estimated using Kaplan–Meier methods. Results: Overall, 36.0% achieved pCR, with the highest rates in HER2-positive (65%) and TNBC (56%) subtypes. Independent predictors of pCR included HER2 positivity (OR 4.21, 95% CI 1.83–9.67, p < 0.001), high Ki-67 > 47.5% (OR 3.62, 95% CI 1.68–7.80, p = 0.001), ER < 10% (OR 2.77, 95% CI 1.18–6.50, p = 0.019), and radiologic complete response (OR 10.03, 95% CI 2.91–34.60, p < 0.001). At a median follow-up of 75 months, compared with non-pCR, patients achieving pCR had a significantly lower risk of recurrence (HR 0.16, 95% CI 0.04–0.70, p = 0.014) with 5-year DFS rates of 91.5% vs. 72.8%. For OS, pCR patients showed a lower risk of death (HR 0.33, 95% CI 0.07–1.49, p = 0.150), corresponding to 5-year OS of 92.2% vs. 87.0%, although this difference was not statistically significant. Conclusions: HER2 positivity, high Ki-67, low ER expression, and radiologic complete response are independent predictors of pCR. Achieving pCR strongly correlates with improved DFS but not OS, likely due to limited sample size and event number. These findings reinforce pCR as a surrogate endpoint in TNBC and HER2-positive disease and highlight the need for post-neoadjuvant escalation in non-pCR patients.

15 June 2022
Verified
Book
Closed access
PDF file
EAEbru Akay
Ebru Akay
MEMehtap Eroğlu
Mehtap Eroğlu
GAGökhan Aytekin
Gökhan Aytekin
SASelma Erol Aytekin
Selma Erol Aytekin
LTLeyla Tekin
Leyla Tekin
OMOrkida Malile
Orkida Malile